Adage Capital Partners
SANA icon

Adage Capital Partners’s Sana Biotechnology SANA Stock Holding History

Adage Capital Partners’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-702,000
Closed -$1.92M – 962
2025
Q2 		$1.92M Buy
+702,000
New +$1.45M ﹤0.01% 763
2021
Q2 		– Sell
-150,000
Closed -$5.02M – 1058
2021
Q1 		$5.02M Buy
+150,000
New +$4.88M 0.01% 798

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners's SANA Position: Q3 2025 in Review

Adage Capital Partners sold out of Sana Biotechnology (SANA) in Q3 2025, closing a stake of 702,000 shares — an estimated $1.92M sold.

Adage Capital Partners first reported a position in SANA in Q1 2021 and held it in 2 quarters. The position peaked at $5.02M in Q1 2021. 178 funds tracked by Wall St. Rank hold SANA as of Q3 2025.

  • Adage Capital Partners reported no remaining Sana Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 702,000 Sana Biotechnology shares in Q3 2025, an estimated $1.92M.
  • Adage Capital Partners first reported a position in Sana Biotechnology in Q1 2021 and held it in 2 quarters.
  • Adage Capital Partners's Sana Biotechnology position peaked at $5.02M in Q1 2021.
  • 178 funds tracked by Wall St. Rank held Sana Biotechnology as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.